Enterprise Value
89.83M
Cash
150.4M
Avg Qtr Burn
-15.58M
Short % of Float
2.95%
Insider Ownership
6.12%
Institutional Own.
87.86%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLYB212 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 1b Data readout | |
RLYB116 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 1 Data readout | |
RLYB211 Details Fetal and Neonatal Alloimmune Thrombocytopenia | Failed Discontinued |